Mechanism of bronchoprotective effects of a novel natriuretic hormone peptide

Journal of Allergy and Clinical Immunology

Volumn 113, Issue 1, 2004, Pages 79-85

  Hellermann, Gary ^a   Kong, Xiaoyuan ^a   Gunnarsdóttir, Jóhanna ^b   San Juan, Homero ^a   Singam, Raji ^a   Behera, Sumita ^a   Zhang, Weidong ^a   Lockey, Richard F ^c   Mohapatra, Shyam S ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF ICELAND   (Iceland)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ANP; Anti inflammatory; Asthma; Bronchodilation; ERK; Natriuretic; NF B; Signaling

Indexed keywords

ANTIINFLAMMATORY AGENT; CALCIUM ION; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; NATRIURETIC FACTOR; NITRIC OXIDE; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHUS; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL ACTIVATION; CELL ASSAY; CELL TYPE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ASSAY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

EID: 0346041505     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2003.10.009     Document Type: Article

References (46)

1. Vesely DL. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002;53:153-9.
2. Misono KS. Natriuretic peptide receptor: structure and signaling. Mol Cell Biochem 2002;230:49-60.
3. Abbey SE, Potter LR. Lysophosphatidic acid inhibits C-type natriuretic peptide activation of guanylyl cyclase-B. Endocrinology 2003;144:240-6.
4. Silberbach M, Roberts CT Jr. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal 2001;13:221-31.
5. Gutkowska J, Cantin M, Genest J, Sirois P. Release of immunoreactive atrial natriuretic factor from the isolated perfused rat lung. FEBS Lett 1987;214:17-20.
6. Hulks G, Jardine AG, Connell JM, Thomson NC. Influence of elevated plasma levels of atrial natriuretic factor on bronchial reactivity in asthma. Am Rev Respir Dis 1991;143:778-82.
7. Di Nardo P, Peruzzi G. Physiology and pathophysiology of atrial natriuretic factor in lungs. Can J Cardiol 1992;8:503-8.
8. Lindberg F, Andersson KE. Vasodilator responses to alpha-human-atrial natriuretic peptide in isolated omental and pulmonary arteries from rabbit and man. Acta Physiol Scand 1988;134:391-7.
9. Tolsa JF, Gao Y, Sander FC, Souici AC, Moessinger A, Raj JU. Differential responses of newborn pulmonary arteries and veins to atrial and C-type natriuretic peptides. Am J Physiol Heart Circ Physiol 2002;282:H273-80.
10. Devillier P, Corompt E, Breant D, Caron F, Bessard G. Relaxation and modulation of cyclic AMP production in response to atrial natriuretic peptides in guinea pig tracheal smooth muscle. Eur J Pharmacol 2001;430:325-33.
11. Mikawa K, Kume H, Takagi K. Effects of atrial natriuretic peptide and 8-brom cyclic guanosine monophosphate on human tracheal smooth muscle. Arzneimittelforschung 1998;48:914-8.
12. Robichaud A, Michoud MC, Saunier C, Duvivier C, Peslin R, du Souich P. Effect of atrial natriuretic peptide on bronchial tone in anesthetized rabbits. Peptides 1993;14:1325-30.
13. Ohbayashi H, Suito H, Takagi K. Compared effects of natriuretic peptides on ovalbumin-induced asthmatic model. Eur J Pharmacol 1998;346:55-64.
14. Angus RM, McCallum MJ, Thomson NC. Effect of inhaled atrial natriuretic peptide on methacholine induced bronchoconstriction in asthma. Clin Exp Allergy 1994;24:784-8.
15. Angus RM, McCallum MJ, Hulks G, Thomson NC. Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma. Am Rev Respir Dis 1993;147:1122-5.
16. Angus RM, Millar EA, Chalmers GW, Thomson NC. Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction. Am J Respir Crit Care Med 1995; 151:2003-5.
17. Mizuguchi M, Myo S, Fujimura M. Bronchoprotective effects of atrial natriuretic peptide against propranolol-induced bronchoconstriction after allergic reaction in guinea pigs. Clin Exp Allergy 2000;30:439-44.
18. Mcalpine LG, Hulks G, Thomson NC. Effect of atrial natriuretic peptide given by intravenous infusion on bronchoconstriction induced by ultrasonically nebulized distilled water (fog). Am Rev Respir Dis 1992;146:912-5.
19. Biollaz J, Callahan LT 3rd, Nussberger J, Waeber B, Gomez HJ, Blaine EH, Brunner HR. Pharmacokinetics of synthetic atrial natriuretic peptides in normal men. Clin Pharmacol Ther 1987;41:671-7.
20. Kumar M, Behera AK, Lockey RF, Vesely DL, Mohapatra SS. Atrial natriuretic peptide gene transfer by means of intranasal administration attenuates airway reactivity in a mouse model of allergic sensitization. J Allergy Clin Immunol 2002;110:879-82.
21. Ishii Y, Watanabe T, Watanabe M, Hasegawa S, Uchiyama Y. Effects of atrial natriuretic peptide on type II alveolar epithelial cells of the rat lung. Autoradiographic and morphometric studies. J Anat 1989;166:85-95.
22. Cvek K, Ridderstrale Y, Gerstberger R. Functional receptors for atrial natriuretic peptide in the rat mammary gland during lactation. Endocrinology 1998;139:2615-21.
23. + concentration. Methods Cell Biol 2002;70:453-74.
24. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG. A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 1993;214:11-6.
25. Holschermann H, Noll T, Hempel A, Piper HM. Dual role of cGMP in modulation of macromolecule permeability of aortic endothelial cells. Am J Physiol 1997;272:H91-8.
26. Howarth PH, Redington AE, Springall DR, Martin U, Bloom SR, Polak JM, et al. Epithelially derived endothelin and nitric oxide in asthma. Int Arch Allergy Immunol 1995;107:228-30.
27. Christman JW, Sadikot RT, Blackwell TS. The role of nuclear factor-kappa B in pulmonary diseases. Chest 2000;117:1482-7.
28. Kook H, Itoh H, Choi BS, Sawada N, Doi K, Hwang TJ, et al. Physiological concentration of atrial natriuretic peptide induces endothelial regeneration in vitro. Am J Physiol Heart Circ Physiol 2003;284:H1388-97.
29. Kiemer AK, Bildner N, Weber NC, Vollmar AM. Characterization of heme oxygenase 1 (heat shock protein 32) induction by atrial natriuretic peptide in human endothelial cells. Endocrinology 2003;144:802-12.
30. + entry in bronchial contraction and remodeling. J Appl Physiol 2002;92:1594-602.
31. +. Am J Respir Cell Mol Biol 2003;28:713-21.
32. Toda M, Tulic MK, Levitt RC, Hamid Q. A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma. J Allergy Clin Immunol 2002;109:246-50.
33. Kiemer AK, Vollmar AM. Elevation of intracellular calcium levels contributes to the inhibition of nitric oxide production by atrial natriuretic peptide. Immun Cell Biol 2001;79:11-7.
34. Kiemer AK, Vollmar AM. Autocrine regulation of inducible nitricoxide synthase in macrophages by atrial natriuretic peptide. J Biol Chem 1998;273:13444-51.
35. Pawliczak R, Cowan MJ, Huang X, Nanavaty UB, Alsaaty S, Logun C, et al. p11 expression in human bronchial epithelial cells is increased by nitric oxide in a cGMP-dependent pathway involving protein kinase G activation. J Biol Chem 2001;276:44613-21.
36. de Boer J, Meurs H, Flendrig L, Koopal M, Zaagsma J. Role of nitric oxide and superoxide in allergen-induced airway hyperreactivity after the late asthmatic reaction in guinea-pigs. Br J Pharmacol 2001;138:1235-42.
37. Silkoff PE, Robbins RA, Gaston B, Lundberg JO, Townley RG. Endogenous nitric oxide in allergic airway disease. J Allergy Clin Immunol 2000;105:438-48.
38. Folkerts G, Nijkamp FP. Airway epithelium: more than just a barrier! Trends Pharmacol Sci 1998;19:334-41.
39. Hamad AM, Johnson SR, Knox AJ. Antiproliferative effects of NO and ANP in cultured human airway smooth muscle. Am J Physiol 1999;277:L910-8.
40. Calderone A. The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases. Heart Fail Rev 2003;8:55-70.
41. Kiemer AK, Weber NC, Vollmar AM. Induction of IkappaB: atrial natriuretic peptide as a regulator of the NF-kappaB pathway. Biochem Biophys Res Commun 2002;295:1068-76.
42. Carini R, De Cesaris MG, Splendore R, Domenicotti C, Nitti MP, Pronzato MA, et al. Mechanisms of hepatocyte protection against hypoxic injury by atrial natriuretic peptide. Hepatology 2003;37:277-85.
43. Kiemer AK, Vollmar AM. The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages. Ann Rheum Dis 2001;60:iii68-70.
44. Kiemer AK, Vollmar AM, Bilzer M, Gerwig T, Gerbes AL. Atrial natriuretic peptide reduces expression of TNF-alpha mRNA during reperfusion of the rat liver upon decreased activation of NF-kappaB and AP-1. J Hepatol 2000;33:236-46.
45. Kiemer AK, Weber NC, Furst R, Bildner N, Kulhanek-Heinze S, Vollmar AM. Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circ Res 2002;90:874-81.
46. Fluge T, Fabel H, Wagner TO, Schneider B, Forssmann WG. Urodilatin (ularitide, INN): a potent bronchodilator in asthmatic subjects. Eur J Clin Invest 1995;25:728-36.